- Original research
- Open Access
Phytol-based novel adjuvants in vaccine formulation: 1. assessment of safety and efficacy during stimulation of humoral and cell-mediated immune responses
© Lim et al; licensee BioMed Central Ltd. 2006
- Received: 20 September 2006
- Accepted: 30 October 2006
- Published: 30 October 2006
The Erratum to this article has been published in Journal of Immune Based Therapies and Vaccines 2007 5:3
Vaccine efficacy depends significantly on the use of appropriate adjuvant(s) in the formulation. Phytol, a dietary diterpene alcohol, is similar in structure to naturally occurring isoprenoid adjuvants; but little is known of its adjuvanticity. In this report, we describe the relative safety and efficacy of phytol and its hydrogenated derivative PHIS-01 compared to commercial adjuvants.
We tested adjuvant properties using a formulation consisting of either a hapten, phthalate-conjugated to a protein, keyhole limpet hemocyanin (KLH), or ovalbumin (OVA) emulsified with the test adjuvants in mice without any surfactant. Humoral immunity was assessed in terms of titer, specificity, and isotypic profiles. The effect on cell-mediated immunity was studied by assaying the induction of either OVA- or B-lymphoma-specific cytotoxic T-lymphocyte (CTL) activity.
Results and Discussion
The phytol compounds, particularly PHIS-01, elicit increased titers of all major IgG subclasses, especially IgG2a. Unlike commercial adjuvants, both phytol compounds are capable of inducing specific cytotoxic effector T cell responses specific to both OVA and B-lymphoma tested. Phytols as adjuvants are also distinctive in that they provoke no adverse anti-DNA autoimmune response. Intraperitoneally administered phytol is comparable to complete Freund's adjuvant in toxicity in doses over 40 ug/mouse, but PHIS-01 has no such toxicity.
These results and our ongoing studies on antibacterial immunity show that phytol and PHIS-01 are novel and effective adjuvants with little toxicity.
- Keyhole Limpet Hemocyanin
- Vaccine Formulation
- Cytotoxic Effector Cell
- Percent Specific Lysis
Designing effective vaccines depends not only on the nature of the antigens (Ag), but also on the inclusion of appropriate adjuvants to ensure optimum induction of protective immunity. The immunogenicity of a protein is inherently linked to its physico-chemical properties, but adjuvants can significantly influence the amplitude of the response. Traditionally, vaccines have consisted of attenuated/killed microorganisms, or isolated components. In recent years, vaccine formulations have included specific and safer recombinant proteins, synthetic peptides, and even vectored DNA [1, 2]. In general, these vaccines are not as effective as those based on whole organisms, but the efficacy is often enhanced when used in conjunction with non-specific immunoadjuvants [3–5].
Adjuvant activity has been demonstrated in numerous natural products through serendipity and by trial and error [6, 7]. However, in selecting adjuvants, their immunological properties are as important as their benefit-to-toxicity ratio. Adjuvants are often foreign to the body and thus capable of producing adverse reactions. These adverse effects can be a direct consequence of toxic or non-metabolizable components in their formulation or can result from the inclusion of agents that overstimulate the immune or inflammatory systems . For example, CFA, which is used widely in experimental studies, produces excellent humoral and cell-mediated immunity, but is unsuitable for human and veterinary purposes because of toxicity. Hence, there is a need for identification of adjuvants that are both safe and efficacious.
The search for potentially useful adjuvants has often led to the use of isoprenoid compounds extracted from plant sources [9–12]. Because some of these compounds can be toxic, we considered developing isoprenoid adjuvants from substances that are common in the human diet. Epidemiological studies suggest that green vegetables in diets improve resistance to infection, and thus enhance immunity [13–15]. They may also help prevent some cancers by augmenting immunological responses against emerging neoplasms in the early stages of carcinogenesis [16–18]. Chlorophylls in green vegetables constitute an important source of an isoprenoid component, phytol (3, 7, 11, 15-tetramethyl-2-hexadecen-1-ol, C20H40O), a branched aliphatic alcohol, also present as the fatty acid side chain in tocopherols. Because phytols are hydrophobic, they are capable of interacting with the cell membrane. A number of recent studies have described various cellular and biological effects of phytol (19–21). However, there is as yet no definitive report on the adjuvanticity of phytol or any synthetic derivatives such as hydrogenated phytol or phytanol, named PHIS-01 (Patent pending) which has been studied in our laboratory.
In this report, we compared the adjuvant potential of both phytol and PHIS-01 to that of some commonly used adjuvants (Complete and incomplete Freund's adjuvants, TiterMax, Ribi's adjuvant system, and Alhydrogel). Since phytol and PHIS-01 are structurally similar to the mineral oil constituents in IFA and CFA, we included pristane for comparison as the protype mineral oil in this study. Most of these common adjuvants are not equally capable of enhancing either humoral and/or cellular responses against an immunogen. Moreover, their inclusion in vaccine formulations can engender adverse side effects, including the induction of anti-DNA antibody responses, the hallmark of lupus-like autoimmune disorders [22, 23]. We demonstrate here that phytol, and to a greater extent phytol-derived PHIS-01, exhibit excellent adjuvanticity at low nontoxic doses and enhance an anti-hapten humoral response that consists of major IgG subclasses, especially IgG2a. They are equally capable of provoking anti-tumor cytotoxic T cell response. Moreover, unlike conventional adjuvants, phytol-derived PHIS-01 shows little toxicity or nephritogenic pathology resulting from induction of a cross-reactive anti-DNA antibody response. In our ongoing study, we have also noted that the phytol and PHIS-01 are superior adjuvants in eliciting anti-bacterial immune responses .
We studied the effects of commercial and experimental adjuvants on different immune parameters such as antigen-specific humoral responses, antibody isotypes, cell-mediated anti-tumor immunity, and autoimmune reactivity in BALB/c, C57Bl/6, and autoimmune-prone NZB mice. Gender-matched, 8–12 weeks old BALB/c and C57Bl/6 mice were bred in the animal facility of Indiana State University. To determine autoimmune parameters, six-week-old NZB/W F1 and NZB female mice (Harlan Sprague Dawley, Indianapolis, IN) were used. All animal experiments were performed according to guidelines of laboratory animal care (NIH publication 85-23), using specific protocols approved by the Animal Care and Use Committee (ACUC) of Indiana State University.
The commercial adjuvants used in this study consisted of CFA, IFA, Titermax, and RAS (Sigma Chemical Co., St. Louis, IL); phytol (Pfaltz and Bauer Inc., Waterbury, CT); and Alhydrogel (Accurate Chemical and Scientific Corp., Westbury, NY). Pristane (Sigma, St. Louis, IL) was also used for comparative assessment of plasmacytomagenic potential. Our experimental adjuvant consisted of phytol and a phytol derivative, PHIS-01 (patent pending). The latter was obtained by chemical reduction of phytol into phytanol following a published procedure .
Anti-tumor vaccine efficacy
A B-cell lymphoma 2C3 was used in this study. We have extensively used this tumor model in previous studies [26–28]. This tumor, which secretes anti-phthalate 2C3-Ig, was generated from fusion of phthalate-KLH-primed BALB/c splenocytes with a non-secreting myeloma, X63-Ag8.653. Two other anti-phthalate hybridomas, designated as 1H5 and 3B4, which show high specificity for phthalate and DNA, were also previously described .
We also studied another tumor model, Ia-negative EL4 thymoma (H-2b) and EL4 cells transfected with ovalbumin (OVA)-cDNA gene (E.G7-OVA) obtained from American Type Culture collection (ATCC, Rockville, MD). Using this tumor model, we assessed OVA-antigen-specific CTL in C57BL/6 mice.
Adjuvants on humoral response
Adjuvant effect on antibody response was studied in BALB/c (five or more in a group) which were injected intraperitoneally (IP) with phthalate-KLH conjugates (in BALB/c) emulsified in experimental or conventional adjuvants in a total volume of 400 μL (100 μg of each antigen). Control groups of mice were immunized with PBS only. Subsequent immunizations also contained adjuvants and were given at 10-day intervals. The mice were bled through retro-orbital veins five days after each immunization.
For assessment of antigen-specific cytotoxic effector activity, we used ovalbumin (OVA in 5 or more C57Bl/6 mice) also emulsified with adjuvants as above. We also assessed the efficacy of adjuvants in generating tumor-specific cytolytic response against the 2C3 tumor model in BALB/c mice. The latter group was repeatedly immunized with killed 2C3 tumor cells before spleens were dissected out for isolation and assessment of cytotoxic effector cells.
Enzyme-linked immunosorbent assays (ELISA)
Indirect ELISA was performed to assess and correlate different humoral responses . Serum antibodies were tested for their specificities to phthalate on polyvinyl 96-well flat bottom plates (Falcon) coated with either phthalate (as a conjugate of BSA) or calf thymus DNA. After the plates were blocked with 1% BSA/PBS O.N. at 4°C, various dilutions of sera (10–10000) were added to each well, and the plates were incubated for 1 hr at 37°C. The wells were washed with phosphate-buffered saline-containing 0.05% triton X, and rabbit anti-mouse Ig-HRP (50 μL) (at 1:3000 dilution) was added. Plates were incubated for 1 hr and washed again. Bound rabbit anti-mouse Ig-HRP was detected by addition of o-phenylene diamine (OPD) and hydrogen peroxide. The reaction was stopped with 50 uL of 10% H2SO4, and the color intensity was read at 490 nm.
Generation of cytolytic effector cells
C57BL/6 mice were given three injections with OVA emulsified in test adjuvants. Spleen cells were obtained from C57Bl/6 mice on day 7 after the 3rd immunization and prepared for 51Cr-release cytotoxicity assay . For lymphoma, BALB/c mice were injected with each adjuvant 5 days before administration of live 2C3 tumor (5 × 106 cells/mouse). Splenocytes were harvested on day 8 and stimulated with killed 2C3 cells before 51Cr-release cytotoxicity assay.
Splenocytes were seeded into 6-well tissue culture plates at 6 × 106 cells/well in 2 ml RPMI/10% FBS, and then stimulated in vitro with killed E.G7-Ova cells or 2C3 cells (1.2 × 106 cells/well) for 5 days in the presence of 10% CO2 at 37°C to generate cytotoxic effector cells.
As previously described, the target cells were labeled at 37°C with 150 μCi of sodium 51Cr for 1 hr, washed three times in PBS, and then resuspended in RPMI/10% FBS . The labeled target cells were then dispensed at 5 × 103 cells/well into 96-well plates. Effector splenocytes were added at various E:T ratios with appropriate target cells seeded in 96-well plates. The total volume of the reaction was 200 μL/well. The plates were incubated at 37°C for 6 h, after which they were centrifuged, and 30 μL of supernatant removed from each well was added to 96-well lumina plates to assess 51Cr release in a Top Count-NXT plate reader (Packard Instruments, Meriden, CT, USA). The percent specific lysis was determined by the formula: percent specific lysis = (sample release - spontaneous release/maximum release - spontaneous release) × 100. Spontaneous release never exceeded 18% of the maximum release. All cytolytic analyses described in this study were performed in triplicate and repeated at least three times in separate experiments. Specifically, the measurement of OVA-specific cytotoxic effector cell activity was performed using E.G7-OVA and EL4 cells as targets in C57Bl/6 mice, the latter serving as the negative control against OVA-specific effectors. For 2C3-lymphoma-specific cytotoxicity studies, 2C3 and a mastocytoma P815 were used as targets. P815 cells served as the negative control.
The paired Student's t-test (Sigma Plot software) was used to determine statistical significance. Levels of p < 0.05 were considered statistically significant. Data are expressed as mean ± S.E.M.
Generation of anti-phthalate antibody response in BALB/c mice
Effects of PHIS-01 and other adjuvants on induction of IgG subclasses
Induction of anti-tumor effector T cells
We previously reported induction of idiotype-specific cytotoxic T-lymphocytes (CTL) in BALB/c mice following prophylactic immunization with killed 2C3 tumors or during early stages of 2C3 tumor growth in vivo . Using this model, we investigated whether this tumor-specific CTL response is augmented by injection of adjuvants and live 2C3 cells. As shown in Fig 3B, splenocytes of mice injected with phytol and particularly, PHIS-01 exhibited significant CTL response against 2C3 tumor target cells. These splenocytes had no cytotoxic activity against antigen-negative control tumors P815 (data not shown). In contrast, the commercial adjuvants CFA/IFA or Alum were ineffective against 2C3 B-lymphoma (Fig. 3B).
Evaluation of toxicity and safety of phytol adjuvants
Comparison of intraperitoneal lethal doses (LD50) and body weights of control mice and those injected with phytol and PHIS-01.
Acute intoxication (% Survival in 24 h)
Mean body weight loss (%)
LD50 (mg/kg body weight)
Average weights and cell numbers of spleens from mice treated with different adjuvants.
Spleen Weight (mg)
Cell Numbers/Spleen (× 107)
Mouse injected with PBS
90.2 ± 5.6
6.5 ± 1.2
Mouse injected with Pristane
110.5 ± 6.4
7.6 ± 0.9
Mouse injected with IFA
160.3 ± 1.3
8.3 ± 0.5
Mouse injected with CFA
642.3 ± 2.4
35.6 ± 2.3
Mouse injected with Phytol (80 μg)
665.6 ± 5.7
42.4 ± 2.2
Mouse injected with PHIS-01 (80 μg)
141.3 ± 3.2
8.1 ± 1.2
Induction of lupus-autoantibodies by adjuvants
No signs of glomerulonephritis in phytol-treated mice
Further evaluation of safety and toxicity was assessed by histopathology of the kidneys from mice treated with phytol, PHIS-01 and IFA/CFA. Blood urea nitrogen (BUN) and proteinuria of autoimmune-prone NZB/W F1 mice immunized with phthalate-KLH in phytols or IFA/CFA were tested for by using Azostix (Bayer, Elkart, IN) and Multistix (Bayer, Elkart, IN) respectively. As described previously , mice immunized with phthalate in IFA/CFA reveal almost 3–4-fold higher BUN and urinary protein level indicating severe nephritis than those of control mice; however, no such kidney pathology was observed using phytol or PHIS-01 as adjuvants (data not shown).
Ascites production in BALB/c mice using pristane and phytols
Ascites production from syngeneic BALB/C mice using various priming agents
Isotype of Ig
Total volume collected (ml)
Mouse number providing ascites/number injected
3Antibody titer (OD @ 490 nm)
IgG1 (γ1, κ)
IgM (μ, κ)
IgM (μ, κ)
The importance of safe and effective adjuvants in vaccine research cannot be overstated, and there is a growing need, not only for new vaccines but for new adjuvants as well. Most newly developed vaccines are based on selected target antigens consisting of single molecules or fragments derived from infectious microorganisms, or tumor cells. They are administered in the form of purified proteins, synthetic peptides, or vectored DNA. Such vaccines are usually poorly immunogenic and costly and/or difficult to produce. Moreover, many widely used vaccines can lose their effectiveness due to repeated use and for other biological reasons. Adjuvants can override such immunological inadequacy and help mount effective immune responses. Although in the past most vaccines have been designed to stimulate antibody responses, vaccines currently in development are increasingly designed to elicit cellular immune responses involving Th1 cells, and CTLs. Such responses are required to control chronic infectious diseases associated with viruses and intracellular pathogens, and also for the development of therapeutic vaccines against cancer.
In this study, we determined the adjuvanticities of chlorophyll-derived phytol and its chemically reduced derivative, PHIS-01, relative to those of commonly used commercial adjuvants. In the first study, mice were immunized with a hapten, phthalate, conjugated to KLH in one of the several adjuvants: phytol, PHIS-01, CFA, IFA, pristane, TiterMax, Ribi adjuvant system, and Alhydrogel or alum. Effectiveness was measured in terms of quantity, specificity, duration, and isotype of Abs generated. In another experiment, phytol, PHIS-01, CFA, and IFA were used to study induction of cell-mediated immunity, especially tumor specific CTL response to either OVA-transfected EL4 thymoma or 2C3 lymphoma in C57Bl/6 and BALB/c mice respectively. In addition, this study also addressed the issue of safety relative to efficacy of phytol-based adjuvants. Safety evaluation has been performed from the perspectives of toxicity, and the ability to induce adverse autoimmune reaction and plasmacytoma formation.
In this report, phthalate-protein conjugate was selected as the immunogen because of our previous finding that the anti-phthalate antibody response induced with IFA as the adjuvant elicits cross-reactive anti-DNA antibodies engendering lupus-like syndromes with kidney pathology [27–29]. We also reported that this adverse cross-reactivity is exacerbated by many commonly used adjuvants. Assessment of anti-phthalate and cross-reactive anti-DNA antibody responses in the presence of various adjuvants is thus a novel approach for evaluating the safety and effectiveness of adjuvants. In this investigation, we observed that phytol and PHIS-01 effectively enhance the immunogenicity of phthalate-conjugate without inducing anti-DNA antibodies. The mechanism underlying the suppression of this autoimmune reaction due to phthalates remains unclear.
Further evidence for the efficacy of phytol, and especially PHIS-01, as adjuvants, can be gleaned from the quality and levels of IgG responses elicited. PHIS-01-treated mice exhibited excellent anti-phthalate IgG2a response. This isotype is most desirable in therapeutic applications, because of its ability to activate complement cascades, and Ab-dependent cellular cytotoxicity which in turn ensures better protection against tumor or parasites. Moreover, induction of IgG2a is an indirect measure of the relative contributions of Th1 and Th2 cells. It remains to be determined whether this isotype switch reflects changes in cytokine milieu brought about by the phytol-based adjuvants.
In many instances, specific antigen-adjuvant combinations have been shown to promote antigen-specific production of Th1 type cytokines of (IFN-γ, IL-2) and cytotoxic T-cell responses [36–38]. However, there is as yet no specific combination that ensures sustained activity in terms of magnitude and duration of cell-mediated immune response. Our studies reveal that mice pre-treated with phytol, and especially PHIS-01, mount an effective CTL response recognizing lymphoma-associated Ig idiotype. Neither CFA/IFA nor alhydorgel appear to induce a similar response. However, when C57Bl/5 mice are immunized with soluble OVA and phytol or PHIS-01, cytotoxic effector activity of their spleen cells exhibit significant enhancement, although not as much as CFA/IFA.
In conclusion, phytol and PHIS-01 adjuvants appear to be more versatile as immunostimulants on the basis of their ability to promote effective humoral and cell-mediated immune responses. This is further evident in another study in which we assessed their adjuvanticity in engendering effective antibacterial responses . In terms of toxicity, PHIS-01 induces little, if any, splenomegaly, implying no significant pro-inflammatory effects, and therefore is more useful than phytol. Further, only small amounts of phytol and PHIS-01 are required to stimulate immune responses. None of these two compounds stimulates reaginic immune responses, nor induces autoimmune lupus-like syndromes. Most importantly, phytol and PHIS-01 support hybridoma propagation in vivo without inducing formation of granulomatous tissue on peritoneal surfaces, which is a problem with pristane. Also, unlike pristane, these novel adjuvants have no effect on plasmacytoma development in BALB/c. In future studies, we plan to determine whether or not the differences in efficacy are due to a distinct cytokine milieu generated by these compounds
The authors thank Professors William Brett and Jim Hughes of the Department of Life sciences and Tista Ghosh, MD, MPH, Tri-County Health Dept, Denver for their valuable suggestions and critical reading of this manuscript. This work was supported by grants from University Research (UNR215) and Indiana Academy of science (SAC131) (to S. G.) and Graduate Student funding from Indiana State University (to S-Y L.).
- Berzofsky JA: Designing peptide vaccines to broaden recognition and enhance potency. Ann NY Acad Sci. 1995, 754: 161-68.View ArticlePubMedGoogle Scholar
- Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE, Morris JC: Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest. 2004, 113: 1515-25. 10.1172/JCI200421926.PubMed CentralView ArticlePubMedGoogle Scholar
- Schijns V: Immunological concepts of vaccine adjuvant activity. Curr Opin Immunol. 2000, 12: 456-63. 10.1016/S0952-7915(00)00120-5.View ArticlePubMedGoogle Scholar
- Vogel FR: Improving vaccine performance with adjuvants. Clin Infect Dis. 2000, 30 (Suppl 3): S266-70. 10.1086/313883.View ArticlePubMedGoogle Scholar
- Burdin N, Guy B, Moingeon P: Immunological foundations to the quest for new vaccine adjuvants. Biodrugs. 2004, 18: 79-93. 10.2165/00063030-200418020-00002.View ArticlePubMedGoogle Scholar
- Chedid L: Adjuvants of immunity. Ann Immunol (Inst Pasteur). 1995, 136D: 283-91.Google Scholar
- Hunter RL: Overview of vaccine adjuvants: present and future. Vaccine. 2002, 20 (Suppl 3): S7-12. 10.1016/S0264-410X(02)00164-0.View ArticlePubMedGoogle Scholar
- Gupta RK, Relyved ER, Lindblad EB, Bizzini B, Ben-Efraim S, Gupta CK: Adjuvant balance between toxicity and adjuvanticity. Vaccine. 1993, 11: 293-306. 10.1016/0264-410X(93)90190-9.View ArticlePubMedGoogle Scholar
- Rilling HC, Breunger E, Epstein WW, Crain PF: Prenylated proteins: the structure of the isoprenoid group. Science. 1990, 247: 318-20. 10.1126/science.2296720.View ArticlePubMedGoogle Scholar
- Kelly MJ: Alpha-tocopherol as agonist in hypoxia. J Pham Phamacol. 1986, 38: 66-8.View ArticleGoogle Scholar
- Schulz S, Buhling F, Ansorge S: Prenylated proteins and lymphocyte proliferation: inhibition by d-limonene related monoterpenes. Eur J Immunol. 1994, 24: 301-7.View ArticlePubMedGoogle Scholar
- Lehne G, Haneberg B, Gaustad P, Johansen PW, Preus H, Abrahamsen TG: Clin Experim Immunol. 2005, 143: 65-69. 10.1111/j.1365-2249.2005.02962.x.View ArticleGoogle Scholar
- Watanabe M, Tomoo T: Anti-inflammatory constituents of topically applied crude drugs. V. Constituents and anti-inflammatory effects of Aoki, Aucuba japonica Thunb. Biol Pharm Bull. 1994, 17: 665-67.View ArticleGoogle Scholar
- Peto R, Doll R, Buckley JD, Sporn MB: Can Dietary beta-carotene materially reduce human cancer rates?. Nature. 1981, 290: 201-8. 10.1038/290201a0.View ArticlePubMedGoogle Scholar
- Hirohata T, Tomita Y, Shibata A: Epidermiology of diet, nutrition, and cancer. J Jpn Soc Food Nutr. 1980, 34: 1-7.Google Scholar
- Busk L, Ahlborg UG: Retinol (Vitamin A) as an inhibitor of the mutagenicity of aflatoxin B. Toxicol Lett. 1980, 6: 243-49. 10.1016/0378-4274(80)90127-7.View ArticlePubMedGoogle Scholar
- Hirayama T: Diet and Cancer. Nutr Cancer. 1999, 1: 67-81.View ArticleGoogle Scholar
- Chernomorsky S, Porets R, Segelman A: Effect of dietary chlorophyll derivatives on mutagenesis and tumor cell growth. Teratog Carcinog Mutag. 1999, 79: 313-22. 10.1002/(SICI)1520-6866(1999)19:5<313::AID-TCM1>3.0.CO;2-G.View ArticleGoogle Scholar
- Steinberg D, Avigan J, Mize CE, Baxter JH, Cammermeyer J, Fales HM, Highet P: Effects of dietary phytol and phytanic acid in animals. J Lipid Res. 1966, 7: 684-91.PubMedGoogle Scholar
- Van den Branden C, Vamecq J, Wybo I: Phytol and peroxisome proliferation. Pediatr Res. 1986, 20: 411-5.View ArticlePubMedGoogle Scholar
- Hibasami H, Kyohkon M, Ohwaki S, Katsuzaki H, Imai K, Ohnishi K, Ina K, Komiya T: Diol- and triol-types of phytol induce apoptosis in lymphoid leukemia Molt 4B cells. Int J Mol Med. 2002, 10: 555-59.PubMedGoogle Scholar
- Satoh M, Reeves WH: Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane. J Exp Med. 1994, 180: 2341-46. 10.1084/jem.180.6.2341.View ArticlePubMedGoogle Scholar
- Satoh M, Kuroda Y, Yoshida H, Behney KM, Mizutani A, Akaogi J, Nacionales DC, Lorenson TD, Rosenbauer RJ, Reeves WH: Induction of autoantibodies by adjuvants. J Autoimmun. 2003, 21: 1-9. 10.1016/S0896-8411(03)00083-0.View ArticlePubMedGoogle Scholar
- Lim S-Y, Bauermeister A, Kjonaas RA, Ghosh SK: Phyol-Based Novel Adjuvants in Vaccine Formulation: 2. Assessment of Safety and Efficacy in the Induction and Protective Immune Responses to Lethal Bacterial infections in Mice. J Immune Based Therapies and Vaccines. 2006, 4: 5-10.1186/1476-8518-4-5.View ArticleGoogle Scholar
- Bendavid A, Burns CJ, Field LD, Hashimoto K, Ridley DD, Sandanayake KRA, Wieczorek L: Solution- and Solid-Phase Synthesis of Components for Tethered Bilayer Membranes. J Org Chem. 2001, 66: 3709-3716. 10.1021/jo0057147.View ArticlePubMedGoogle Scholar
- Lim SY, Laxmanan S, Stuart G, Ghosh SK: Anti-Lymphoma Immunity: Relative efficacy of peptide and recombinant DNA vaccine. Cancer Detect Prev. 2001, 25: 470-8.PubMedGoogle Scholar
- Lim SY, Ghosh SK: Autoreactive responses to an environmental factor: 1. Phthalate induces antibodies exhibiting anti-DNA specificity. Immunology. 2003, 110: 482-92. 10.1111/j.1365-2567.2003.01765.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Lim SY, Ghosh SK: Autoreactive responses to an environmental factor: 2. Phthalate-induced anti-DNA specificity is down-regulated by autoreactive cytotoxic T cells. Immunology. 2004, 112: 94-104. 10.1111/j.1365-2567.2004.01842.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Lim SY, Ghosh SK: Autoreactive responses to an environmental factor: 3. Mouse strain-specific differences in induction and regulation of anti-DNA antibody responses due to phthalate isomers. J Autoimmunity. 2005, 25: 33-45. 10.1016/j.jaut.2005.04.002.View ArticleGoogle Scholar
- Santra S, Sood AK, Ghosh SK: Cytotoxic effector T cells elicited by the killed tumor vaccine differ significantly from the effectors generated during active growth of a murine B-cell lymphoma. Cancer Immunol Immunother. 1999, 48: 421-29. 10.1007/s002620050618.View ArticlePubMedGoogle Scholar
- Bendelac A, Medzhitov R: Adjuvants of immunity: harnessing innate immunity to promote adaptive immunity. J Exp Med. 2002, 195: F19-23. 10.1084/jem.20020073.PubMed CentralView ArticlePubMedGoogle Scholar
- Hoebe K, Janssen E, Beutler B: The interface between innate and adaptive immunity. Nat Immunol. 2004, 5: 971-74. 10.1038/ni1004-971.View ArticlePubMedGoogle Scholar
- Potter M, Robertson CL: Development of plasma cell neoplasms in BALB/c mice after intraperitoneal injection of paraffin oil adjuvant, heat-killed staphylococcus mixtures. J Natl Cancer Inst. 1960, 31: 847-61.Google Scholar
- Potter M, Boyce C: Induction of plasma neoplasms in strain of BALB/c mice with mineral oil and mineral oil adjuvants. Nature. 1962, 193: 1086-87. 10.1038/1931086a0.View ArticlePubMedGoogle Scholar
- Anderson PN, Potter M: Induction of plasma tumors with 2,6,10,14-Tetramethylpentadecane (Pristane). Nature. 1969, 222: 994-6. 10.1038/222994a0.View ArticlePubMedGoogle Scholar
- Gillette RW: Alternatives to pristane priming for ascitic fluid and monoclonal antibody production. J Immunol Method. 1987, 99: 21-23. 10.1016/0022-1759(87)90027-5.View ArticleGoogle Scholar
- Moingeon P, Haensler J, Lindberg A: Towards the rational design of Th1 adjuvants. Vaccine. 2001, 19: 4363-437. 10.1016/S0264-410X(01)00193-1.View ArticlePubMedGoogle Scholar
- Kaesh SM, Wherry EJ, Ahmed R: Effector and memory T cell differentiation: implications for vaccine development. Nat Rev Immunol. 2002, 2: 336-45. 10.1038/nri797.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.